CD209 antigen could be a promising target for preventing severe COVID-19
Researchers reveal how two genetic variations may contribute to COVID-19 disease severity and suggest the product of one, the CD209 antigen, may be a potential drug target.
List view / Grid view
News
Endosomal trafficking could be a target for Alzheimer’s therapies
Researchers have shown that 70 percent of Alzheimer’s patients have high levels of proteins associated with dysfunction in the endosomal trafficking system in their spinal fluid.
Computational model used to predict drug targets against SARS-CoV-2
A model of a human lung cell has been used to understand how SARS-CoV-2 uses host cell processes to reproduce, revealing drug targets.
Proteogenomic analysis offers insights into paediatric brain tumours
The first comprehensive survey of genomics, transcriptomics, global proteomics and phosphoproteomics has revealed insights into paediatric brain tumours.
Epidemiological data on SARS-CoV-2 uncovers insights into mutations
Researchers have analysed 750 samples from patients with SARS-CoV-2 to discover details about its transmission and mutational properties.
Tetracycline antibiotics show promise against Zika virus
A new study shows that methacycline, a commonly used antibiotic, can reduce the neurological damage caused by Zika virus infections in mice.
Network modelling reveals a potential new Alzheimer’s therapy
Researchers used integrative network biology analysis to identify the molecular mechanisms that may drive Alzheimer’s and identified a potential therapeutic intervention.
Simple molecule could combat antibiotic-resistant gonorrhoea and meningitis, study shows
An inexpensive molecule showed efficacy against antibiotic-resistant Neisseria gonorrhoeae and Neisseria meningitidis in an animal model.
New insight to guide discovery of drugs targeting ion channels
The study shows how drug-like small molecules inhibit the activity of Transient Receptor Potential Canonical 1/4/5 (TRPC1/4/5) channels and could transform the development of future therapies.
3D view of SARS-CoV-2 replication cycle could enable antiviral drug development
Scientists have shown how SARS-CoV-2 induces changes in the architecture of host cells to drive replication and made their data available to all.
Antibodies from previous COVID-19 infection protect patients for six months
A study in healthcare workers has shown that antibodies from COVID-19 infection protect individuals from reinfection for at least six months.
Novel inhibitor kills brain cancer cells missing ENO1 in mice, study shows
In pre-clinical studies, researchers have shown that a new therapy called POMHEX can destroy brain cancer cells that were missing one of two genes encoding the enolase enzyme.
MALP cells as a potential target for osteoporosis drug development
Researchers have found that bone marrow adipogenic lineage precursor (MALP) cells may initiate the production of osteoclasts and drive bone remodelling in osteoporosis.
Drug target and candidate for paediatric heart failure identified
A group of researchers has found a drug candidate named TRV027 that can increase the cardiac contractility of neonatal mice.
Antibody effector functions are key to combatting COVID-19, finds study
Rodent studies show that using antibodies with different targets and modes of action in combination is more effective at preventing and treating COVID-19.
